Business Wire

GUESS Heads to Granada for the 2022 Fall/Winter Advertising Campaign

Share

The new GUESS Fall-Winter 2022 advertising campaign sees the brand off to explore the history-steeped streets of Granada, Spain.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005098/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

GUESS Heads to Granada for the 2022 Fall/Winter Advertising Campaign (Photo: Business Wire)

The FW22 campaign is immortalized through the lens of fashion photographer Tatiana Gerusova, under the guidance of GUESS?, Inc.’s Chief Creative Officer, Paul Marciano. The new campaign features a sizzling lineup: German-born, Polish fashion model Kim Dammer, Serbian model Nina Kostić, Spanish model Lidia Santos, Italian model Mario Ermito, and French model Xavier Grey.

GUESS Women

The campaign showcases an enticing array of GUESS pieces, highlighting must-have accessories and elevated animal and botanical prints. The collection brings a fresh and youthful breeze of contemporary color and style to grey winter days.

Against the alluring continental backdrop of the Moorish Alhambra Palace and the ancient Arabic quarter of Albaicín, we see the GUESS woman enveloped in ravishing, cosmopolitan looks. The collection includes striking two-piece pant sets and flirty skirt suits, hour-glass sweater dresses, and shimmering, pleated gowns, all teamed with statement-making winter coats, cozy knits, waist-nipping belts, and sassy high-heel boots.

The FW22 GUESS Women’s collection and campaign work to showcase a modern yet timeless offering that embraces the female spirit of glamour and independence. Ranging from an assortment of warm-and-fuzzy color swatches including pretty pastels, bright blues, and autumnal reds, to time-honored neutrals, like beige, cream, brown, grey and khaki, the line offers a range of color for all season long.

GUESS Men

From boyishly causal to effortlessly smart, the GUESS man steps out in everything from ever-cool leather and denim to flashes of tie-dye, and boy-next-door checks. Rounding out the collection, the line incorporates camouflage pants, elegant sweaters, impeccably tailored coats, puffer jackets and rugged parkas. With the season’s eclectic range of footwear, accessories, and color tones, which range from classic blues, and earthy hues, to flashes of yellow, peach and pastel, the collection will appeal to both the elegant man-about-town and the eternal wanderer.

“I absolutely love this collection and location, it’s so spellbinding,” said Chief Creative Officer, Paul Marciano. “Granada’s mix of Baroque, Moorish, and Renaissance architecture creates a really striking contrast with the warm colors and contemporary look and feel of the Fall-Winter offering. It’s a place of unique and iconic beauty, where tradition, the past and present merge together, an element that really embodies the glamorous and timeless essence of GUESS.”

Look out for the 2022 GUESS Fall-Winter advertising campaign in leading international fashion and lifestyle magazines, GUESS stores and online.

About GUESS?, Inc.

Established in 1981, GUESS began as a jeans company and has since successfully grown into a global lifestyle brand. Guess?, Inc. designs, markets, distributes and licenses a lifestyle collection of contemporary apparel, denim, handbags, watches, eyewear, footwear and other related consumer products. Guess? products are distributed through branded Guess? stores as well as better department and specialty stores around the world. As of April 30, 2022, the Company directly operated 1,073 retail stores in the Americas, Europe and Asia. The Company’s partners and distributors operated 565 additional retail stores worldwide. As of April 30, 2022, the Company and its partners and distributors operated in approximately 100 countries worldwide. For more information about the Company, please visit www.guess.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kaitlyn Quail
GUESS?, Inc.
212.852.0568
kquail@guess.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye